Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States
- Howard University Hospital
Washington D.C., District of Columbia, United States
- Mayo Clinic in Florida
Jacksonville, Florida, United States
- Johns Hopkins University
Baltimore, Maryland, United States
- University of Maryland Greenebaum Cancer Center
Baltimore, Maryland, United States
- Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
- Mayo Clinic
Rochester, Minnesota, United States
- University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2003
- Primary completion
- 30 Jun 2007
- Completion
- —
- Last update posted
- 4 Jun 2013
- Registered enrollment
- 58
- Registry id
- NCT00062244
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.